Showing results (121-130 of 198) with videos related to
Sort By:
Pageof 20
The Lancet. Haematology|December 24, 2019
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 studyRoger G Owen, Helen McCarthy, Simon Rule, et al.The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.NEJM Evidence|February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid CancersMichael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.Pediatric Neurology|February 3, 2026
Antiseizure Prescription for Children With Severe Congenital Heart Defects and Children With Gastrointestinal AnomaliesMads Damkjaer, Joan K Morris, Elisa Ballardini, et al.The Journal of Allergy and Clinical Immunology|July 30, 2015
Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control studyEster Garne, Anne Vinkel Hansen, Joan Morris, et al.Journal of Virology|October 3, 2014
Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacyRachel H Fong, Soma S R Banik, Kimberly Mattia, et al.International Journal of Environmental Research and Public Health|March 11, 2023
Hospital Length of Stay and Surgery among European Children with Rare Structural Congenital Anomalies-A Population-Based Data Linkage StudyEster Garne, Joachim Tan, Mads Damkjaer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2017
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaMyron S Czuczman, Marek Trněný, Andrew Davies, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2013
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximabBertrand Coiffier, Weimin Li, Erin D Henitz, et al.Therapeutic Advances in Hematology|April 4, 2022
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK studyAdam J Mead, Nauman M Butt, Waseem Nagi, et al.Pageof 20